Neomorph
Neomorph is a San Diego-based clinical-stage biotech founded in 2020 that engineers molecular glue degraders — small molecules inducing targeted protein degradation via E3 ligases — to address historically undruggable disease-causing proteins, serving global Big Pharma partners (AbbVie, Novo Nordisk, Biogen) through collaboration and licensing deals.
- Company typePrivate
- Founded2020
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Neomorph does
Neomorph, Inc. is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company engineers molecular glue degraders — small molecules that induce targeted protein degradation by creating neomorphic protein-protein interactions between E3 ubiquitin ligases and disease-causing neo-substrates — to address proteins historically considered undruggable by conventional small-molecule approaches. Neomorph's lead wholly-owned asset, NEO-811, is an oral molecular glue degrader designed to degrade ARNT (HIF-1β) and is currently in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma.
The company's core technology is a next-generation molecular glue discovery platform that integrates a proprietary E3 ubiquitin ligase database spanning hundreds of ligases beyond the industry-standard cereblon, multiple novel degrons beyond the canonical G-loop motif, proprietary glue libraries (including DNA-Encoded Library screening capabilities), world-class structural biology via X-ray crystallography and cryo-EM, and proprietary AI/ML algorithms for predictive interface compatibility and de novo glue design. The company was founded by scientific founders Eric Fischer, Benjamin Ebert, and Scott Armstrong — co-authors of the foundational 2014 Nature and Science papers that defined the cereblon molecular glue field — alongside President and CEO Philip Chamberlain, with former Celgene Chairman/CEO Robert J. Hugin serving as Chairman of the Board.
Neomorph monetizes through multi-year collaboration and licensing agreements with global Big Pharma partners rather than through product sales, with three active deals (AbbVie, Novo Nordisk, Biogen) carrying combined potential value approaching $5 billion and individual deals reported at up to $1.46–$1.64 billion each in upfront payments, R&D funding, development and commercialization milestones, and tiered royalties. The company has raised over $200 million in private venture capital within the six months preceding May 2026, including a $100 million Series B led by Deerfield Management in April 2026, and is expanding operations into a new 80,000-square-foot Class A laboratory facility in Sorrento Mesa, San Diego, with full transition expected in 2026.
Neomorph firmographics
Firmographics- Name
- Neomorph
- Legal name
- Neomorph, Inc.
- Website
- https://neomorph.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Neomorph is a San Diego-based clinical-stage biotech founded in 2020 that engineers molecular glue degraders — small molecules inducing targeted protein degradation via E3 ligases — to address historically undruggable disease-causing proteins, serving global Big Pharma partners (AbbVie, Novo Nordisk, Biogen) through collaboration and licensing deals.
- Ownership category
- akta.pro rank
Neomorph industry classification
Industry- Product category
- Targeted Protein Degradation Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Neomorph is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Neomorph business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Pharma Partnership and Licensing Income: Pre-revenue from product sales; revenue derived from multi-year collaboration and licensing agreements with Big Pharma (AbbVie, Novo Nordisk, Biogen), with combined potential value approaching $5 billion. Typical deal economics include upfront payments, ongoing R&D funding, development and commercialization milestone payments, and tiered royalties on future sales. Three active Big Pharma collaborations are reported at up to $1.46–$1.64 billion each.
- Venture Capital Financing (Non-Revenue Capital): Equity capital from venture financing rounds (e.g., $100 million Series B closed in April 2026 led by Deerfield Management with participation from Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital of Dana-Farber Cancer Institute) used to fund clinical development and platform expansion rather than recognized as operating revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Neomorph product offering
Product offeringCore offering
Neomorph engineers molecular glue degraders — small molecules that induce targeted degradation of disease-causing proteins by creating new (neomorphic) protein-protein interactions with E3 ubiquitin ligases. The company operates a proprietary discovery platform combining an expansive E3 ligase database, novel degron libraries, proprietary glue libraries with DEL screening, structural biology, and AI/ML-driven rational design. Its lead asset NEO-811 is in a Phase 1/2 trial for clear cell renal cell carcinoma, and Neomorph monetizes its platform through multi-year collaboration and licensing agreements with Big Pharma.
Differentiator
Problem solved
Functional benefit
Products and services
- NEO-811 A potent, selective, orally bioavailable molecular glue degrader designed to induce targeted degradation of ARNT (HIF-1β), blocking HIF signaling in clear cell renal cell carcinoma (ccRCC). Currently in a first-in-human Phase 1/2 clinical trial as monotherapy in patients with locally advanced or metastatic non-resectable ccRCC. Wholly owned by Neomorph.
- Molecular Glue Discovery Platform Neomorph's next-generation, rational-design drug discovery platform for molecular glue degraders. Features the world's largest proprietary molecular glue target space with multiple novel degrons, unique glue libraries, an expansive portfolio of E3 ubiquitin ligases beyond cereblon, and proprietary AI/ML capability for rational prospective drug discovery. Licensed to Big Pharma partners for co-development of candidates.
- Undisclosed Solid Tumors Program Undisclosed molecular glue degrader program targeting solid tumors, positioned in Neomorph's pipeline between discovery and IND-enabling stages.
- Early-Stage Pipeline Programs (Multiple Indications) Discovery-stage molecular glue degrader programs being explored across multiple indications (oncology, immunology, neurodegeneration, virology, cardiometabolic, and rare disease) as part of Neomorph's broader pipeline, including defined targets in oncology/immunology and neurology.
Quantifiable outcome
- Targeted protein degradation market projected to grow from $5.95B (2025) to $12.44B (2034) — the addressable market for Neomorph's molecular glue modality.
- +2 more outcomes
Companies that use Neomorph
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
Neomorph technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Neomorph partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship.
- AbbVieflagshipMulti-year collaboration and licensing partnership for molecular glue degraders, publicly reported at up to $1.64 billion in deal value. The partnership is referenced alongside AbbVie's broader AI and biotech deal-making strategy (e.g., BigHat Biosciences, Capstan Therapeutics), positioning Neomorph as a strategic platform partner for AbbVie in targeted protein degradation. Listed as a partner on Neomorph's website.
- Novo NordiskflagshipMulti-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Biogen. Listed as a partner on Neomorph's website, supporting Neomorph's platform reach into cardiometabolic and rare disease indications in Novo Nordisk's therapeutic focus.
- BiogenflagshipMulti-year collaboration and licensing partnership for molecular glue degraders. Part of combined partnership potential value approaching $5 billion disclosed alongside AbbVie and Novo Nordisk. Listed as a partner on Neomorph's website, providing Neomorph with a partner in neurology indications aligned with Biogen's therapeutic focus.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Neomorph competitors and assessment
Company assessmentDirect peers
- Proxygen: Proxygen is a discovery-stage TPD company developing molecular glue degraders using a proprietary screening platform including yeast- and mammalian-cell based glue discovery. Directly comparable to Neomorph in glue discovery platform technology, with multiple Big Pharma collaborations.
- Kymera Therapeutics: Kymera is a clinical-stage TPD biotech developing heterobifunctional degraders and molecular glues, with active Sanofi partnership. Directly comparable to Neomorph in TPD platform development, oncology/inflammation focus, and pharma collaboration strategy.
- BioTheryX: BioTheryX develops targeted protein degraders (PHM) for hematological malignancies, including IMiD-based approaches. Comparable to Neomorph in TPD modality with cereblon-modulator expertise, and similar clinical-stage development profile.
- C4 Therapeutics: C4 Therapeutics develops degronimid-based molecular glue degraders (e.g., cemsidomide) with active partnerships including Biogen and Merck KGaA/Roche. Closely comparable to Neomorph in glues with novel ligase binding modes and multi-program Big Pharma collaborations.
- Foghorn Therapeutics: Foghorn develops chromatin-based cancer therapies including a degrader platform targeting chromatin regulatory complexes. Comparable to Neomorph in protein degradation for oncology, with a platform approach and clinical-stage pipeline.
- Amphista Therapeutics: Amphista is a clinical-stage TPD biotech developing bifunctional and molecular glue degraders with active Bristol Myers Squibb partnership. Comparable to Neomorph in non-cereblon ligase targeting, protein degradation modality, and Big Pharma partnership structure.
- Monte Rosa Therapeutics: Monte Rosa develops molecular glue degraders for immunology and oncology indications using a quaternary structure-based platform and AI-enabled design. Directly comparable to Neomorph in glue-based TPD, AI-driven discovery, and clinical-stage pipeline focus.
- Arvinas: Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders (e.g., vepdegestrant with Pfizer). Directly comparable to Neomorph in TPD modality, both cereblon- and non-cereblon-based degrader development, and BD-led Big Pharma partnership model.
Broad incumbents
- Novartis: Novartis is a major pharma with active TPD and degrader research programs across oncology and other therapeutic areas. Comparable as a broad incumbent in protein degradation with the capital and commercial reach to in-license or acquire molecular glue platforms like Neomorph's.
- Bristol Myers Squibb: Bristol Myers Squibb is a major pharma with extensive CELMoD (cereblon modulator) franchise (lenalidomide/pomalidomide-derived degraders) via Celgene acquisition and Amphista partnership. Comparable as a broad incumbent in protein degradation with both internal pipeline and external platform partnership strategy that mirrors Neomorph's BD motion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neomorph social profiles
Digital presenceNeomorph financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neomorph leadership team
Management profileNumber of profiles
Profiles1 record
Neomorph funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neomorph M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neomorph
What does Neomorph do?
Neomorph engineers molecular glue degraders — small molecules that induce targeted degradation of disease-causing proteins by creating new (neomorphic) protein-protein interactions with E3 ubiquitin ligases. The company operates a proprietary discovery platform combining an expansive E3 ligase database, novel degron libraries, proprietary glue libraries with DEL screening, structural biology, and AI/ML-driven rational design. Its lead asset NEO-811 is in a Phase 1/2 trial for clear cell renal cell carcinoma, and Neomorph monetizes its platform through multi-year collaboration and licensing agreements with Big Pharma.
Is Neomorph a public or private company?
Neomorph is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neomorph founded?
Neomorph was founded in 2020. It employs 51 to 100 people.
Where is Neomorph based?
Neomorph is headquartered in San Diego, United States, in the North America region.
How does Neomorph make money?
Two revenue lines are on record. Pharma Partnership and Licensing Income is the primary driver. The others are venture Capital Financing (Non-Revenue Capital).
Who are Neomorph's main competitors?
Direct peers on record are Proxygen, Kymera Therapeutics, BioTheryX, C4 Therapeutics, Foghorn Therapeutics, Amphista Therapeutics, Monte Rosa Therapeutics and Arvinas. Broad incumbents are Novartis and Bristol Myers Squibb.
Does Neomorph have an API?
No public API is recorded for Neomorph.
What industry is Neomorph in?
Neomorph's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.